SquamousCellCarcinomaofSkin near Largo, FL

Care Philosophy: Dr Richard Kim is a Service Chief of Medical Gastrointestinal Oncology and Senior Member in the Gastrointestinal Oncology Department at Moffitt Cancer Center. He is a Professor of Oncology at the University of South Florida College of Medicine. Dr Kim received his medical degree from the University of Miami School of Medicine and completed a residency in internal medicine at the University of Illinois at Chicago. He pursued a postdoctoral fellowship in hematology and medical oncology at Yale University Comprehensive Cancer Center in New Haven, CT.

Care Philosophy: Dr Nishihori is a senior member in the Blood & Marrow Transplant and Cellular Immunotherapy (BMT CI) Department at Moffitt Cancer Center and is a professor in the Department of Oncologic Sciences at the University of South Florida. Dr Nishihori's clinical interests include autologous and allogeneic hematopoietic cell transplantation (HCT) as well as cellular immunotherapeutic approaches for the treatment of various hematologic malignancies including but not limited to multiple myeloma, plasma cell dyscrasias, amyloidosis, malignant lymphomas, acute and chronic leukemias, myelodysplastic syndrome, myelofibrosis and myeloproliferative disorders. He also performs autologous HCT for testicular cancer/germ cell tumor.

Biography: Dr. Victoria Rizk is a board-certified medical oncologist who specializes in the care and treatment of patients with breast cancer. Prior to joining Tampa General, Dr. Rizk worked as a medical oncologist at Memorial Sloan Kettering Cancer Center in New York City, where she provided comprehensive care, support and education for patients with breast cancer. Additionally, she was an instructor in medicine at Weill Medical College of Cornell University. Dr. Rizk graduated from an accelerated, six-year B.A./M.D. program at the University of Missouri-Kansas City School of Medicine. She then completed Internal Medicine Residency at the University of South Florida Morsani College of Medicine and Hematology/Oncology Fellowship at the University of South Florida/Moffitt Cancer Center in Tampa. Skilled in clinical research, Dr. Rizk is credited with several peer-reviewed publications, abstracts and presentations. Dr. Rizk has memberships with the American Society of Clinical Oncology, the European Society for Medical Oncology, the American College of Physicians and the American Medical Association.

Care Philosophy: Gustavo Rivero, MD, is a dual fellowship-trained hematology and medical oncologist specializing in the treatment of acute and chronic leukemia. Dr Riveros areas of clinical expertise includes: acute and chronic myeloid leukemias, acute lymphoid leukemias, myelodysplastic syndrome, myeloproliferative neoplasm, and clonal hematopoiesis of indetermined potential (CHIP).

Care Philosophy: Dr Celeste Bello isa double board-certified hematologist and medical oncologist, and a senior member in the Malignant Hematology program at Moffitt Cancer Center. She joined the faculty at Moffitt Cancer Center in 2008 after completing her fellowship at the University of South Florida. Dr Bello has developed special expertise in managing patients with Hodgkin's and non-Hodgkin's lymphomas, a special category within the broader group of hematologic (blood) malignancies. Examples of non-Hodgkin's lymphomas include follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma.

Care Philosophy: Dr Creelan earned his MD from Jefferson Medical College. He completed an Internal Medicine Residency at Thomas Jefferson University in the Department of Internal Medicine. Dr Creelan then completed a Hematology Oncology Fellowship at the University of South Florida at Moffitt Cancer Center anda Master's Degree in Clinical and Translational Research through the National Institute of Health K30-sponsored SPOR program. Dr Creelan will focus on translational and clinical research, specifically the development of new immune therapies, for the treatment of lung cancers. His research efforts aim to more effectively treat these cancers based on new insights into the biology of the disease.